Eyevensys Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $29.7M
Latest Deal Amount
  • Investors
  • 11

Eyevensys General Information

Description

Developer of therapeutic proteins intended to address critical unmet needs in ophthalmology. The company's proteins not only improve short and long term therapeutic outcomes but also enhance compliance, improve ocular bioavailability and tolerability, enabling physicians to deliver enhance results to their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Tour Maine Montparnasse
  • 33, avenue du Maine
  • 75015 Paris
  • France
+33 01 00 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyevensys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 08-Jan-2020 $29.7M 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series A) 27-Sep-2016 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 11-Apr-2013 $259K $2.35M Completed Startup
1. Early Stage VC 14-May-2012 $2.09M $2.09M 000.00 Completed Startup
To view Eyevensys’s complete valuation and funding history, request access »

Eyevensys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
To view Eyevensys’s complete cap table history, request access »

Eyevensys Executive Team (5)

Name Title Board Seat Contact Info
Patricia Zilliox Ph.D Chief Executive Officer
Francine Behar-Cohen MD Founder, Board Member & Chief Scientific Officer
Ronald Buggage MD Chief Medical Officer
To view Eyevensys’s complete executive team members history, request access »

Eyevensys Board Members (8)

Name Representing Role Since
Catherine Boule Karista (France) Board Member 000 0000
Chahra Louafi Bpifrance Board Member 000 0000
François Thomas MD Eyevensys Board Member 000 0000
Frank Kalkbrenner MD Boehringer Ingelheim Board Member 000 0000
Garth Cumberlidge Ph.D Self Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Eyevensys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyevensys Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
GF Securities PE/Buyout Minority 000 0000 000000 0
Pureos Bioventures Venture Capital Minority 000 0000 000000 0
Quark Venture Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Pontifax Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »